Recurrent C. Diff Infection
VIDEO: Real-world data confirm Rebyota’s ‘consistent’ efficacy in recurrent C. difficile
WASHINGTON — In a Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, discusses real-world results for Rebyota as a treatment of recurrent Clostridioides difficile infection, which were presented at Digestive Disease Week.
Live biotherapeutics may be paradigm shift in C. difficile GIs have been waiting for
Nearly half a million Americans are diagnosed with Clostridioides difficile infection each year. Although often treated with antibiotics, C. difficile recurrence is possible. However, recently developed therapies may change this paradigm.
FDA-approved microbiome therapy reduces recurrent CDI, regardless of risk factors
An FDA-approved oral fecal microbiota therapeutic reduces the risk for recurrent Clostridioides difficile infection in high-risk patients compared with placebo, regardless of demographics or baseline risk factors, researchers reported.
Novel alternative to fecal microbiota therapy prevents recurrent CDI in study
A novel oral microbiome-directed therapy called VE303 successfully prevented recurrent Clostridioides difficile infection in adults at high risk for recurrence, researchers found.